Mirum Pharmaceuticals, Inc. Investment Income, Interest
Mirum Pharmaceuticals, Inc. (MIRM) reported Investment Income, Interest of $3.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-06-30 was $3.85M, a 26.97% increase year-over-year.
- Mirum Pharmaceuticals, Inc. investment income, interest for the quarter ending 2026-03-31 was $3.40M, a 12.50% increase year-over-year.
- Mirum Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-12-31 was $3.42M, a 6.74% increase year-over-year.
- Mirum Pharmaceuticals, Inc. investment income, interest for the quarter ending 2025-09-30 was $3.25M, a 6.28% decline year-over-year.
- Mirum Pharmaceuticals, Inc. investment income, interest for fiscal 2025 was $12.73M, a 7.72% decline from fiscal 2024.
- Mirum Pharmaceuticals, Inc. investment income, interest for fiscal 2024 was $13.79M, a 0.41% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. investment income, interest for fiscal 2023 was $13.73M, a 256.11% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. investment income, interest for fiscal 2022 was $3.86M, a 953.83% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 8 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.85M 10-Q · filed 2026-08-05 | $7.25M 10-Q · filed 2026-08-05 | $10.67M derived: sum of 3 quarters · filed 2026-08-05 | $13.92M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $3.40M 10-Q · filed 2026-05-06 | $6.82M derived: sum of 2 quarters · filed 2026-05-06 | $10.07M derived: sum of 3 quarters · filed 2026-05-06 | $13.11M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.67M derived: sum of 2 quarters · filed 2026-02-25 | $9.70M derived: sum of 3 quarters · filed 2026-08-05 | $12.73M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $3.25M 10-Q · filed 2025-11-04 | $6.28M derived: sum of 2 quarters · filed 2026-08-05 | $9.31M 10-Q · filed 2025-11-04 | $12.51M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $3.03M 10-Q · filed 2026-08-05 | $6.06M 10-Q · filed 2026-08-05 | $9.26M derived: sum of 3 quarters · filed 2026-08-05 | $12.73M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $3.02M 10-Q · filed 2026-05-06 | $6.23M derived: sum of 2 quarters · filed 2026-05-06 | $9.70M derived: sum of 3 quarters · filed 2026-05-06 | $13.18M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.67M derived: sum of 2 quarters · filed 2026-02-25 | $10.16M derived: sum of 3 quarters · filed 2026-02-25 | $13.79M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $3.47M 10-Q · filed 2025-11-04 | $6.96M derived: sum of 2 quarters · filed 2025-11-04 | $10.59M 10-Q · filed 2025-11-04 | $14.36M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $3.49M 10-Q · filed 2025-08-06 | $7.12M 10-Q · filed 2025-08-06 | $10.89M derived: sum of 3 quarters · filed 2026-02-25 | $14.96M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $3.63M 10-Q · filed 2025-05-07 | $7.41M derived: sum of 2 quarters · filed 2026-02-25 | $11.47M derived: sum of 3 quarters · filed 2026-02-25 | $15.10M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.84M derived: sum of 2 quarters · filed 2026-02-25 | $11.46M derived: sum of 3 quarters · filed 2026-02-25 | $13.73M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $4.06M 10-Q · filed 2024-11-12 | $7.69M derived: sum of 2 quarters · filed 2024-11-12 | $9.96M 10-Q · filed 2024-11-12 | $12.10M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $3.63M 10-Q · filed 2024-08-07 | $5.90M 10-Q · filed 2024-08-07 | $8.04M derived: sum of 3 quarters · filed 2025-02-26 | $9.39M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $2.27M 10-Q · filed 2024-05-08 | $4.42M derived: sum of 2 quarters · filed 2025-02-26 | $5.77M derived: sum of 3 quarters · filed 2025-02-26 | $6.06M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $3.50M derived: sum of 2 quarters · filed 2025-02-26 | $3.79M derived: sum of 3 quarters · filed 2025-02-26 | $3.86M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $1.35M 10-Q · filed 2023-11-02 | $1.65M derived: sum of 2 quarters · filed 2023-11-02 | $1.71M 10-Q · filed 2023-11-02 | $1.78M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-06-30 | $293.00K 10-Q · filed 2023-08-07 | $362.00K 10-Q · filed 2023-08-07 | $427.00K derived: sum of 3 quarters · filed 2024-03-15 | $499.00K derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-03-31 | $69.00K 10-Q · filed 2023-05-04 | $134.00K derived: sum of 2 quarters · filed 2024-03-15 | $206.00K derived: sum of 3 quarters · filed 2024-03-15 | $286.00K derived: sum of 4 quarters · filed 2024-03-15 | |
| 2021-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $137.00K derived: sum of 2 quarters · filed 2024-03-15 | $217.00K derived: sum of 3 quarters · filed 2024-03-15 | $366.00K 10-K · filed 2024-03-15 | |
| 2021-09-30 | $72.00K 10-Q · filed 2022-11-09 | $152.00K derived: sum of 2 quarters · filed 2022-11-09 | $301.00K 10-Q · filed 2022-11-09 | $469.00K derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $80.00K 10-Q · filed 2022-08-04 | $229.00K 10-Q · filed 2022-08-04 | $397.00K derived: sum of 3 quarters · filed 2022-08-04 | $634.00K derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $149.00K 10-Q · filed 2022-05-05 | $317.00K derived: sum of 2 quarters · filed 2022-05-05 | $554.00K derived: sum of 3 quarters · filed 2022-05-05 | $959.00K derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $405.00K derived: sum of 2 quarters · filed 2022-03-09 | $810.00K derived: sum of 3 quarters · filed 2022-03-09 | $1.56M 10-K · filed 2022-03-09 | |
| 2020-09-30 | $237.00K 10-Q · filed 2021-11-15 | $642.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.39M 10-Q · filed 2021-11-15 | $2.14M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $405.00K 10-Q · filed 2021-08-05 | $1.15M 10-Q · filed 2021-08-05 | $1.90M derived: sum of 3 quarters · filed 2021-08-05 | $2.69M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $749.00K 10-Q · filed 2021-05-06 | $1.50M derived: sum of 2 quarters · filed 2021-05-06 | $2.28M derived: sum of 3 quarters · filed 2021-05-06 | $2.75M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $1.53M derived: sum of 2 quarters · filed 2021-03-09 | $2.00M derived: sum of 3 quarters · filed 2021-03-09 | $2.23M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $785.00K 10-Q · filed 2020-11-12 | $1.25M derived: sum of 2 quarters · filed 2020-11-12 | $1.49M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $468.00K 10-Q · filed 2020-08-06 | $700.00K 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $232.00K 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | $72.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |